View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Deals Analysis
July 16, 2019

US pharma industry sees a drop of 30.5% in deal activity in June 2019

The US pharma industry saw a drop of 30.5% in overall deal activity during June 2019, when compared with the last 12-month average, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

A total of 57 deals worth $14.44bn were announced in June 2019, compared to the 12-month average of 82 deals.

Venture financing was the leading category in the month in terms of volume with 41 deals which accounted for 71.9% of all deals.

In second place was M&A with 12 deals, followed by private equity with four transactions, respectively accounting for 21.05% and 7.02% of overall deal activity in the country’s pharma industry during the month.

In terms of value of deals, M&A was the leading deal category in the US pharma industry with total deals worth $13.36bn, while venture financing and private equity deals totalled $749.83m and $322.3m, respectively.

US pharma industry deals in June 2019: Top deals

The top five pharma industry deals accounted for 93.4% of the overall value during June 2019.

The combined value of the top five pharma industry deals stood at $13.48bn, against the overall value of $14.44bn recorded for the month. The top announced US pharma industry deal tracked by GlobalData in June 2019 was Pfizer’s $11.4bn acquisition of Array BioPharma.

In second place was the $1bn acquisition of Exonics Therapeutics by Vertex Pharmaceuticals and in third place was Merck &Inc’s $773m acquisition of Tilos Therapeutics.

The $200m private equity deal with Esperion Therapeutics by Oberland Capital Management and Upsher-Smith Laboratories’ asset transaction with Dr. Reddy’s Laboratories for $110.5m held fourth and fifth positions, respectively.

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.

 

Related Companies

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU